Immunosenescence is the gradual deterioration of immune function associated with aging. Immunosenescence diminishes immunological responsiveness, heightens susceptibility to infections, and fosters chronic illnesses. Triphala was said to change the immune system in healthy people by increasing the number of B and T lymphocytes and natural killer (NK) cells. Nonetheless, there has been no previous investigation about the use of Triphala in the older population. This first research aims to investigate the immunomodulatory effects of Triphala in older individuals by assessing the proportions of leukocyte subpopulations and cytokine levels in the bloodstream. For four weeks, participants were randomly assigned to receive either 3,232 mg of Triphala or a placebo. There were no major side effects. The research revealed no significant changes in the proportions of leukocyte subsets and cytokine levels in the Triphala group compared to the placebo. These surprising findings could be because older people have fewer types of good gut flora, which makes it harder for Triphala to turn into active chemicals. The power of statistical tests is also poor since the sample size is tiny. In conclusion, taking 3,232 mg of Triphala every day for four weeks is safe, however it did not have a big effect on the immunological response in older people. Additional research is necessary to assess the impact of Triphala on leukocyte function using an expanded cohort.